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We investigated 27 pleomorphic carcinomas of the lung for exon 1 K-ras gene mutations using polymerase
chain reaction–single-strand conformation polymophism analysis and direct sequencing. All pleomorphic
carcinomas were biphasic, that is, composed of an adeno-, squamous- or large-cell-carcinomatous component
associated with a spindle- and/or giant-cell component. Of 27 cases, six (22%) showed K-ras codon 12
mutations, which is a figure higher than that previously reported on in pure sarcoma-like pleomorphic
carcinomas. Five tumors displayed the same mutation in both the epithelial and the sarcomatoid components,
whereas in one tumor the mutation was restricted to the epithelial component. All mutations occurred in
smokers, and were transversions, including GGT (glycine) to TGT (cysteine) change in two cases, to GCT
(alanine) in two and to GTT (valine) in two. No significant relationships were found between the occurrence and
type of mutations and patients’ survival or any other clinicopathological variable, suggesting that K-ras
mutations are early events in the development of these tumors. Our results indicate that most, though not all,
biphasic pleomorphic carcinomas of the lung are monoclonal in origin, and that cigarette smoking may have a
causative role in the development of K-ras alterations in these tumors, as all mutations are transversions.
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Non-small-cell lung carcinomas are morphologically
heterogeneous tumors including three major histo-
logical subtypes, namely adenocarcinoma, squa-
mous cell carcinoma and large-cell carcinoma.1,2
Among most uncommon subtypes, there are poorly
differentiated tumors composed of an intimate
admixture of carcinoma and sarcoma or sarcoma-
like components accounting for 5% or less of all
non-small-cell lung carcinomas. These tumors have
been variously designated in the past as biphasic
and monophasic sarcomatoid carcinoma, pleo-
morphic carcinoma, spindle cell carcinoma, giant
cell carcinoma, pseudosarcoma, pulmonary blasto-
ma and carcinosarcoma.3–19 The latest recommenda-
tions of the World Health Organization have
eliminated most of these terms,1 confirming the
designation of pleomorphic carcinomas to either
pure neoplasms consisting of sarcomatoid spindle
and giant tumor cells or biphasic neoplasms con-
taining sarcomatoid spindle and/or giant cell com-
ponents (accounting for at least 10% of the tumor
mass) and conventional non-small-cell lung carci-
noma, including squamous cell carcinoma, adeno-
carcinoma or large-cell carcinoma. These tumors
may be differentiated from carcinosarcomas for the
lack of a true malignant heterologous mesenchymal
component, such as bone, cartilage, vessels or
skeletal muscle,10 and from pulmonary blastomas
for the lack of primitive mesenchymal and epithelial
Received 13 June 2003; revised 30 October 2003; accepted 11
November 2003; published online 27 February 2004
Correspondence: Dr G Pelosi, MD, MIAC, Divisione di Anatomia
Patologica e Medicina di Laboratorio, Istituto Europeo di
Oncologia, Via G. Ripamonti, 435, I-20141 Milano, Italy.
E-mail: giuseppe.pelosi@ieo.it
Modern Pathology (2004) 17, 538–546
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00
www.modernpathology.org
tumor cells.1,20 Pleomorphic carcinomas are basi-
cally thought to be epithelial tumors in which
neoplastic cells undergo an epithelial–mesenchymal
transition21 and express vimentin and other me-
senchymal proteins.3,7,13–15,17,19,22
In different anatomical sites, most, but not all, of
these tumors composed of carcinoma and sarcoma
or sarcoma-like components are considered mono-
clonal growths (the so-called divergent hypothesis)
rather than true collision tumors (convergent hy-
pothesis).20,23–31 In turn, these monoclonal growths
may originate from a single ancestor undergoing
divergent epithelial and mesenchymal differentia-
tion early during the neoplastic transformation
(combination theory), or the full-blown carcinoma
cells undergo sarcomatoid changes during tumor
progression (conversion theory).21,23–25
In the lung, a monoclonal origin has been
suggested for carcinosarcoma and blastoma using
diverse molecular strategies, such as X chromosome
inactivation,24 microsatellite analysis,29 and muta-
tional genotyping of p53 gene,28 whereas little is
known about clonality of pulmonary pleomorphic
carcinomas.28
Using laser-assisted microdissection of formalin-
fixed and paraffin-embedded sections, we have
investigated the prevalence of K-ras codon 12
mutations in 27 biphasic pleomorphic carcinomas,
in both the epithelial and sarcomatoid components.
Our results indicate that six of 27 (22%) cases
showed K-ras codon 12 mutations, which is a figure
higher than that previously reported on in pure
sarcoma-like pleomorphic carcinomas.32,33 Five
pleomorphic carcinomas had the same mutation in
the epithelial and sarcomatoid components, suggest-
ing a monoclonal origin from a single ancestor.
Materials and methods
Patients
A total of 27 consecutive cases of pulmonary
biphasic pleomorphic carcinomas were retrieved
from the Surgical Pathology files of the City Hospital
in Verona and the European Institute of Oncology in
Milan, Italy. The clinical characteristics of the
patients are summarized in Table 1. There were 25
male and two female cases (M : F ratio 1 : 0.08), aged
from 39 to 79 years (mean7s.d.: 62.7710.2 years;
median 64 years). All but one (PLC-26) patient were
cigarette smokers, and all but five had local or
systemic symptoms at the time of diagnosis, with a
Karnowsky’s performance status ranging from 70 to
100%. Complete follow-up information was avail-
able for all patients, with a mean duration of
37.3737.8 months (median 18; range 2–114). Re-
current disease at different sites was seen in 15
(56%) patients, 12 (44%) of which died of disease.
Table 1 Clinical data of 27 patients with pleomorphic carcinoma
Case # Age/sex Site Symptoms PS Site of relapse DFS
(months)
OS
(months)
Outcome Stage
pTNM
PLC-2 73/M LLL Cough 90 Thoracic wall 16 16 AWD IIB
PLC-3 72/M RUL Dyspnea 90 CNS 12 18 DOD IA
PLC-4 48/F RUML Hemoptysis 100 Bone, CNS, lung 71 90 DOD IB
PLC-5 62/M RLML Cough, fever 90 Lung 38 66 DOD IA
PLC-6 75/M RUL — 90 — 110 110 AW IA
PLC-7 55/M LUL Fever, cough 80 — 2 2 AW IIB
PLC-8 72/M LUL Hemoptysis 80 — 13 13 AW IIB
PLC-10 59/M LLL Thoracic pain 100 — 78 78 AW IA
PLC-11 54/M RUL Thoracic pain 90 Bone 15 10 DOD yIIB
PLC-12 64/M LLL Cough 80 Bone 24 31 DOD IB
PLC-13 71/M RUML Hemoptysis 90 — 80 80 AW IB
PLC-14 69/M RUL Cough, Fever 80 — 114 114 AW IB
PLC-15 72/M LUL — 100 Liver, peritoneum 15 13 DOD IIB
PLC-16 75/M RUL Hemoptysis, thoracic pain 90 Bone 2 6 DOD IB
PLC-17 56/M RUL Cough, fever 90 — 26 26 AW yIIIA
PLC-18 64/M RUL Hemoptysis, cough 90 CNS 3 3 AWD yIIIA
PLC-19 61/M LLL Cough 100 — 79 79 AW IB
PLC-20 71/M LLL Cough, dyspnea 90 Lung 27 36 DOD IB
PLC-21 50/M RUL Hemoptysis 90 Thoracic wall 6 4 DOD IIB
PLC-22 39/M LUL Thoracic pain 100 — 30 30 AW IIB
PLC-23 66/F RUL — 100 — 78 78 AW IA
PLC-24 58/M RUL — 100 Bone 2 6 DOD IB
PLC-25 76/M LUL Cough, fever 80 Bone 4 25 DOUDa IB
PLC-26 63/M RLL — 90 Lung 9 23 DOD IB
PLC-27 56/M RUL Hemoptysis 100 — 88 88 AW IA
PLC-28 43/M RLML Cough, fever, Thoracic pain 100 Thoracic wall, Liver 5 8 DOD IIIA
PLC-29 69/M LLL Cough, dyspnea 100 — 2 2 DOUDb IIB
M: male; F: female; LLL: left lower lobe; RUL: right upper lobe; RUML: right upper-middle lobe; RLML: right lower-middle lobe; LUL: left upper
lobe; RLL: right lower lobe; PS: performance status; DFS: disease-free survival; OS: overall survival; DOUD: died of unrelated disease (aAcute
heart failure. bAdult respiratory distress syndrome); AWD: alive with disease; DOD: died of disease; AW: alive and well; y: neoadjuvant or
postoperative chemotherapy or radiotherapy.
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Two patients (PLC-25 and PLC-29) died of unrelated
disease, that is, acute heart failure and adult
respiratory distress syndrome, respectively. Accord-
ing to the revised international system for staging
lung cancer,1 there were 16 patients with either
p-stage IA (six cases) or IB (10 cases), and 11 with
either p-stage IIB (eight cases) or IIIA (three cases).
Three patients with disease stage IIB and IIIA
underwent neoadjuvant or postoperative che-
motherapy or radiotherapy, whereas patients with
disease stage I did not receive any additional
therapy.
For each case, all paraffin blocks were retrieved,
and archival hematoxylin and eosin sections re-
viewed. The diagnosis of pleomorphic carcinoma
was rendered according to the current WHO guide-
lines.1 Percentage and patterns of the sarcomatoid
(spindle, giant or mixed, the latter being composed
of both spindle and giant cells) and the epithelial
(adeno-, squamous- or large-cell carcinoma) compo-
nents, vascular invasion and tumor necrosis were
assessed for every tumor. Necrosis was evaluated
semiquantitatively on a scale from absent to 2þ
(1þ if r50% and 2þ if 450% of the whole tumor
area).
Immunohistochemistry
The immunohistochemical experiments were per-
formed using monoclonal antibodies to vimentin
(clone V9, Dako, Glostrup, Denmark; dilution 1:50),
cytokeratins (clone AE1-AE3, Novocastra Labora-
tories, Newcastle upon Tyne, UK; dilution 1:50),
epithelial membrane antigen (clone E29, Dako;
dilution 1:20), and carcinoembryonic antigen
(CEA) (clone 11-7, Dako; dilution 1:50), and a
commercially available detection kit (EnVision
Plus-HRP, Dako), according to either the manufac-
turer’s suggestions or previously refined immuno-
histochemical methods.34,35 In each tumor, the
sarcomatoid and epithelial components were as-
sessed separately, recording the percentage of
neoplastic cells immunoreactive for the different
antigens in either components.
Microdissection and K-ras Gene Analysis
For each tumor, different areas corresponding to the
epithelial and sarcomatoid component were micro-
dissected from 3 mm-thick hematoxylin- and- eosin-
stained sections using a computer-assisted laser
micro-dissector (Leica Microsystem, Milan, Italy)
according to the manufacturer’s instructions. Tu-
mors were entirely scanned if 2 cm or less in size,
while two representative tissue blocks were used
in larger neoplasms to avoid any bias in the
sampling procedure. A total of 16 000–20 000
tumor cells were detached from the epithelial
and the sarcomatoid components for genotyping.
An equivalent amount of normal cells was micro-
dissected from the surrounding pulmonary parench-
yma or bronchial-associated lymphoid tissue of
each case. All microdissected fragments were
separately placed into microcentrifuge tubes and
digested overnight at 551C in lysis buffer containing
400 mg/ml proteinase K.
DNAwas amplified for K-ras exon 1 using specific
primers: forward 50-GACTGAATATAAACTTGTGG-
30, reverse 50-CTGTATCAAAGAATGGTCCT-30. Poly-
merase chain reaction (PCR) was run in 50 ml final
volume, containing 1 PCR Buffer II (Applied
Biosystems), 2mM MgCl2 (Applied Biosystems),
200 mM dNTPs (Amersham Bioscience), 0.5 mM of
each primers and 0.025U/ml AmpliTaq DNA Poly-
merase (Applied Biosystems). The conditions for
PCR were denaturation at 941C for 30 s, annealing at
551C for 30 s, and extension at 721C for 30 s. Two
rounds of 30 cycles were used.
K-ras mutations were detected using PCR–single-
strand conformation polymorphism (PCR-SSCP)
analysis and direct DNA sequencing. For PCR-SSCP,
PCR products (5 ml) were mixed with 10 ml of gel
loading solution (75% deionized formamide, 12mM
NaOH, 6mM EDTA and 0.05% xylene cyanol and
bromophenol blue), denaturated at 951C for 2min
and kept on ice until loading on a 15% nondenatur-
ating polyacrylamide gel (30:1 acrylamide:bisacry-
lamide). To improve band resolution, wells were
casted in a 5% polyacrylamide stacking gel. Gels,
containing a 1 TBE buffer were run with a
discontinuous buffer system (25mM tris and
192mM glycine). Electrophoresis was performed at
90V for 17–18h on a PROTEAN II XI cell (BIORAD)
at room temperature, and the gels were stained with
0.1% AgNO3. Results of SSCP analysis were con-
firmed performing two independent experiments,
and the DNA samples of all cases exhibiting aberrant
bands were sequenced as described.36 Appropriate
positive (SW480) and negative (HT29) control cell
lines were used in parallel in all experiments for the
evaluation of point mutations of exon 1 of the K-ras
gene.
Statistical Analysis
Associations of categorical variables were evaluated
by Fisher’s exact t-test or w2-test to determine the
statistical significance of differences in clinico-
pathological data according to the presence or
absence of K-ras gene mutations. Continuous data
were expressed using median values and contrasted
employing the Wilcoxon signed-rank test. Overall
survival was defined as the time between surgery
and the last follow-up or lung cancer-related death.
If a patient died without cancer recurrences, the
patient’s survival time was censored at the time of
death. Only lung cancer-related deaths or recur-
rences were considered as events. Disease-free
survival was calculated from the date of surgery to
the date of progression or the date of the last follow-
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up. Survival estimates were calculated with
Kaplan–Meier’s method and compared by the log
rank test. All analyses were carried out using the SAS
statistical software (SAS Institute, Inc., Cary, NC,
USA). All P-values were based on two-sided testing,
and confidence intervals were set at a 95% level.
Results
Pathological Characteristics of Pleomorphic
Carcinomas
The pathological findings are summarized in Table
2. Grossly, the tumors ranged from 1.9 to 17 cm, with
marginal differences in the median values according
to tumor stage (4 cm in stage I vs 5.5 cm in stage II–
IIIA) (P¼ 0.064). Representative histological features
of pleomorphic carcinomas are shown in Figure 1.
The epithelial component was poorly differentiated
in all but two moderately differentiated cases, and
the sarcomatoid component accounted for 15–90%
of the whole neoplasms (Figure 1a). The spindle cell
sarcomatoid component was either bland-appearing
resembling fibrosarcoma or highly atypical resem-
bling malignant fibrous histiocytoma (Figure 1b).
Giant cells exhibited multilobated and bizarre
nuclei and abundant eosinophilic cytoplasms,
sometimes engulfing leukocytes (Figure 1c). The
mixed pattern resulted from a variable proportion of
highly atypical giant and spindle tumor cells (Figure
1d). Three tumors showed squamous cell carcinoma
associated with mixed (two cases) or spindle (one
case) sarcomatoid components, 11 tumors showed
adenocarcinoma associated with mixed (eight
cases), giant (two cases) or spindle (one case)
sarcomatoid components, and 12 tumors large-cell
carcinoma associated with mixed (six cases), giant
(five cases) or spindle (one case) cells. One tumor
(PLC-28) included a triple epithelial component
(bronchioloalveolar carcinoma, adenocarcinoma
and squamous cell carcinoma) associated with a
spindle cell component. Tumor necrosis was en-
countered in all but four cases, ranging from focal
(o50% of the whole tumor) in nine cases, to diffuse
(450%) in the remaining 14 tumors. Vascular
invasion was recognizable in 16 (59%) cases.
The immunohistochemical results are summar-
ized in Table 3. The epithelial component, indepen-
dent of the histological type, size and stage of
the tumor was more consistently and more
intensely immunoreactive for cytokeratins and
epithelial membrane antigen, whereas the oppo-
site occurred for vimentin (Figures 1e and f).
CEA immunostaining was observed in only 16
tumors, where it was restricted to the epithelial
component.
Table 2 Pathological characteristics of 27 patients with pleomorphic carcinoma
Case # Size
(cm)
Epithelial
component
(EPC)
Grading of
EPC
Pleomorphic
component
(PLC)
% PLC Vascular
invasion
Tumor
necrosis
Ras
mutations
PLC-2 3.6 LCC G3 Giant 40 Yes ++ No
PLC-3 1.9 LCC G3 Mixed 40 No ++ No
PLC-4 6.5 LCC G3 Mixed 90 No ++ No
PLC-5 2.5 SCC G2 Spindle 15 No 0 No
PLC-6 1.8 AC G3 Mixed 60 Yes 0 No
PLC-7 5.5 AC G2 Mixed 80 Yes ++ Yes
PLC-8 5.5 AC G3 Spindle 80 No ++ Yes
PLC-10 1.5 AC G3 Mixed 50 Yes 0 No
PLC-11 4.5 LCC G3 Mixed 75 No + No
PLC-12 5 LCC G3 Giant 25 No + No
PLC-13 9 AC G3 Giant 80 No ++ No
PLC-14 8 LCC G3 Spindle 50 No ++ Yes
PLC-15 5.5 LCC G3 Mixed 50 No ++ No
PLC-16 4 LCC G3 Giant 40 No 0 No
PLC-17 7.5 AC G2 Mixed 90 Yes + No
PLC-18 3.5 AC G2 Mixed 70 Yes + No
PLC-19 6 SCC G3 Mixed 40 Yes + No
PLC-20 4 LCC G3 Giant 40 Yes + No
PLC-21 9 AC G3 Mixed 60 Yes ++ Yes
PLC-22 10.5 LCC G3 Giant 50 No + No
PLC-23 2.2 AC G3 Giant 25 Yes ++ No
PLC-24 6 AC G3 Mixed 30 Yes ++ No
PLC-25 11 AC G2 Mixed 65 Yes ++ Yes
PLC-26 3.5 LCC G3 Mixed 40 Yes + Yes
PLC-27 3 LCC G3 Mixed 15 Yes + No
PLC-28 17 AC/BAC/SCC G3 Spindle 70 Yes ++ No
PLC-29 10.5 SCC G3 Mixed 45 Yes ++ No
LN: number of mediastinal lymph nodes excised during surgery; % PLC: percentage of the pleomorphic component within individual tumors;
AC: adenocarcinoma; LCC: large-cell carcinoma; SCC: squamous cell carcinoma; ADS: adenoasquamous carcinoma; BAC: bronchioloalveolar
carcinoma; mixed: spindle and giant cell components; necrosis: 0, absent; +, o50%; ++, 450%.
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Figure 1 Representative histological features of pulmonary pleopmorphic carcinoma are shown. A typical biphasic appearance is
presented, with epithelial cells resembling those of a conventional lung adenocarcinoma (black asterisk), and sarcomatoid spindle tumor
cells resembling those of fibrosarcoma (a). The spindle cell component may be highly atypical mimicking a malignant fibrous
histiocytoma (b). Giant cells are bizarre with multilobated nuclei and abundant eosinophilic cytoplasm filled by leucocytes (c). The
mixed sarcomatoid pattern results from a variable proportion of highly atypical giant (arrows) and spindle tumor cells (d). The epithelial
component reacts strongly for cytokeratins, whereas the sarcomatoid cells are more occasionally stained (arrows) (e);
vimentin immunostaining decorates especially the sarcomatoid tumor cells, whereas the epithelial cells are less immunoreactive
(white asterisks) (f).
Table 3 Individual results of the immunohistochemical study (all values are %)
All stages Stage I Stage 4I
Marker Mean7s.d. Median P-value Mean7s.d. Median P-value Mean7s.d. Median P-value
CK E 75.1714.7 80 o0.001 71.7718.6 80 0.001 80.070.0 80 o0.001
CK PL 31.2725.7 18 39.1727.7 31.5 19.5717.9 18
Vim E 27.9727.4 18 o0.001 29.4726.7 18 0.004 25.9729.6 18 o0.001
Vim PL 68.6723.1 80 63.1727.7 80 76.8710.5 80
EMA E 67.9720.6 80 o0.001 69.1737.3 80 0.002 66.4722.8 80 0.011
EMA PL 31.4730.5 18 16.7729.5 31.5 26.1731.3 2.5
CEA E 13.9721.9 2.5 0.004 13.4719.7 10.3 0.073 14.9725.7 0 0.020
CEA PL 3.8710.1 0 6.3712.5 0 0 0
E: epithelial; PL: pleomorphic; CK: cytokeratins; Vim: vimentin; EMA: epithelial membrane antigen; CEA: carcinoembryonic antigen.
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K-ras Mutations in Pleomorphic Carcinomas
The results are summarized in Table 2 and repre-
sentative examples shown in Figure 2. K-ras point
mutations at codon 12 were found in six (22%) of
the 27 cases of pleomorphic carcinomas, whereas no
mutation was present in the corresponding normal
lung tissue. All K-ras mutations were confined to
smoking male patients. The mutated cases were four
adenocarcinomas and two large-cell carcinomas
with mixed (four cases) or spindle (two cases)
sarcomatous components. Four tumors showing a
squamous cell carcinoma component, either alone
or associated with adenocarcinoma, had no K-ras
mutations. In all, but one, pleomorphic carcinoma
with mutated K-ras, an identical mutation was
detected in both the epithelial and the sarcomatoid
components. All point mutations were G:C-T:A
and G:C-C:G transversions. In particular, the
normal DNA sequence GGT (encoding glycine) at
codon 12 was changed to TGT (cysteine) in two
cases (PLC-14 and PLC-21), to GCT (alanine) in two
cases (PLC-7 and PLC-8) and to GTT (valine) in one
case (PLC-25). In the remaining case (PLC-26), the
sequence GGT was altered to GTT (valine) in the
epithelial component only, whereas the sarcomatoid
cells had a germline sequence. No significant
relationship was found between the occurrence
and type of K-ras mutations and the different
clinicopathological variables under evaluation, in-
cluding tumor type, size and stage, presence of
necrosis or vascular invasion, age at diagnosis,
gender, and performance status. In particular, no
difference in survival was noted between the six
patients with tumors carrying K-ras mutations and
the 21 patients with tumors lacking K-ras mutations
(Figure 3).
Discussion
The results of the current study on a series of 27
biphasic pleomorphic carcinomas of the lung may
be summarized as follows: (i) K-ras mutations
occured in 22% of the cases; (ii) the same K-ras
mutation was detected in both the epithelial and
sarcomatoid components of the same tumor in all,
but one case, consistent with a monoclonal origin of
the two morphologically distinct components; (iii)
all the present and the previously reported K-ras
mutations are transversions, consistent with a
smoke-related origin of these gene alterations.
The prevalence of K-ras mutations in the current
series of biphasic pleomorphic carcinomas is
slightly different from that recently reported in two
other series of pulmonary pleomorphic carcino-
mas.28,32,33 The different proportion of K-ras muta-
tions among these three series, however, most likely
Figure 2 A PCR–SSCP analysis of K-ras exon 1 in pleomorphic
carcinoma is presented. The cases PLC-14 and PLC-7 show the
same abnormal bands in both the epithelial (E) and sarcomatoid
(PL) components with respect to the matched normal DNA (N). In
case PLC-26, an abnormal band pattern is present in the epithelial
component only, while the sarcomatoid component shows the
same pattern as the normal DNA. Lack of the lower SSCP bands in
the sarcomatoid component of case PLC-14 is due to the loss of
the second K-ras allele, as in the SW480 control cell line (Cþ ).
Figure 3 Overall (a) and disease-free (b) survival curves of PC
patients according to K-rasmutations are shown. No difference in
survival is noted between the six patients with tumors carrying
K-ras mutations and the 21 patients with tumors lacking K-ras
mutations.
K-ras in pleomorphic carcinoma of the lung
G Pelosi et al
543
Modern Pathology (2004) 17, 538–546
depends on the type of the epithelial component of
pleomorphic carcinomas. In fact, in one series, K-ras
mutations were absent in 12 biphasic neoplasms
predominantly composed of squamous cell carcino-
ma associated with spindle cells,28 and in the
second published series, a 12% prevalence of
mutations was reported among 25 pure pleomorphic
carcinomas, including exclusively spindle- and
giant-cell tumors.32,33 At variance with these two
series, the epithelial component of our biphasic
pleomorphic carcinomas was largely represented of
adenocarcinoma and large-cell carcinoma. As a
matter of fact, among the common lung cancer
histotypes, K-ras gene mutations are found in 10–
35% of non-small-cell lung carcinomas, especially
adenocarcinoma and large-cell carcinomas, and
uncommonly in squamous cell carcinomas.37,38
In the current series, K-ras mutations were found
in four (36%) of 11 cases with adenocarcinoma
and in two (16%) of 12 with large-cell carcinoma
morphology.
In the lung, a monoclonal origin has been
suggested for carcinosarcoma and blastoma using
a variety of molecular approaches in a small
number of analyzed tumors, including one carcino-
sarcoma examined for hypoxanthine-phosphoribo-
syl transferase gene polymorphism,24 five cases of
carcinosarcomas evaluated for 12 polymorphic
microsatellite markers,29 and one carcinosarcoma
and one blastoma studied for p53mutations.28 In the
present investigation, we found K-ras point muta-
tions in 6/27 (22%) tumors. The occurrence of the
same point mutation in both the epithelial and the
sarcomatoid component within individual tumors
supports a monoclonal origin for most of these
biphasic pleomorphic carcinomas, with a statistical
odds of only one in 32 for the two distinct neoplastic
populations of undergoing the same allele inactiva-
tion by random chance alone. Our findings are in
keeping with a previous report on a smaller series of
biphasic pleomorphic carcinomas (all composed of
squamous and spindle cell carcinoma) using p53
gene mutational analysis for the assessment of
clonality.28 The latter report suggests a monoclonal
histogenesis of pulmonary biphasic pleomorphic
carcinomas from a totipotent cell by finding iden-
tical p53 mutations in both the epithelial and
sarcomatoid components.28 A single tumor in our
series (case PLC-26), however, harbored a K-ras
mutation in the epithelial but not the sarcomatoid
cells, raising the possibility of a biclonal origin for
few of these tumors, in keeping with similar
findings described also in biphasic carcinomas of
the female genital tract.25
Another interesting finding of our investigation
is that the sarcomatoid cells in our clonally
mutated pleomorphic carcinomas retained variable
phenotypic expressions of diverse epithelial mar-
kers evaluated according to the percentage of
immunoreactive tumor cells, such as cytokeratins,
epithelial membrane antigen and/or CEA, whereas
showed a strong prevalence of mesenchymal mar-
kers, such as vimentin. This differential distribution
between the two cell components was independent
of tumor stage (Table 3). Therefore, we speculate that
biphasic pleomorphic carcinomas may either be
metaplastic carcinomas derived from trans-differen-
tiation of malignant epithelial cells into sarcoma-
like cells (according to the conversion theory) or
arise from a common progenitor that shows an early
divergent bi-directional differentiation (according to
the combination theory). Our hypothesis of a
metaplastic origin of biphasic pleomorphic carcino-
mas is also supported by three other recent studies,
two immunohistochemical dealing with pleo-
morphic carcinomas19,22 and another genetic dealing
with carcinosarcomas of the lung.28 In the latter, a
multistep progression of the sarcomatous compo-
nent from a common totipotent ancestor through an
intermediate stage of carcinoma was prospected, as
these tumors showed a greater amount of genetic
damages in the mesenchymal than in the epithelial
component.28
The association between smoking and pulmonary
pleomorphic carcinomas is very strong,7,14,15,17,32 as
re-emphasized also by the current series of patients,
in whom all but one were smokers. All K-ras
mutations detected in our tumors were transver-
sions, namely G:C-T:A in four cases and G:C-C:G
in two cases, exactly paralleling the findings of
previous reports showing a higher prevalence of
G:C-T:A (67%) than G:C-C:G transversions
(33%).32,33 As transversions resulting from DNA
adducts are most often observed in polycyclic
aromatic hydrocarbon-exposed smokers, it is likely
that a cigarette smoke-related mechanism is in-
volved in the K-ras gene alterations of the subset of
mutated pulmonary pleomorphic carcinomas. Inter-
estingly, an Ile–Val polymorphism of the CYP1A1*2
exon 7, encoding an inducible extrahepatic enzyme
activating polycyclic aromatic hydrocarbons, has
recently been found in 76% of pleomorphic carci-
nomas (as compared with 12% of the normal
population).33 Finally, the lack of any relationship
between occurrence of K-ras mutations and any
indicator of tumor aggressiveness, such as preva-
lence of sarcomatoid cells, size, stage, presence of
vascular invasion, and patients’ survival, could
indicate that K-ras mutations are early events in
the development of biphasic pleomorphic carcino-
mas of the lung, as one would expect from a
promutagenic factor, such as cigarette smoke. The
lack of any relationship with survival and the
relatively small number of mutated tumors in our
investigation, however, suggest that K-ras gene
mutations are not critical events in the development
and malignancy progression of pulmonary pleo-
morphic carcinomas.
In conclusion, we here indicate that most pleo-
morphic carcinomas of the lung are monoclonal as
determined by microdissection-based K-ras gene
mutational analysis, and that cigarette smoke may
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have a causative role in the development of these
mutations because all mutations are transversions.
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